4 April 2018 - - Following a 15-year career, Hyderabad, India-based integrated pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) COO Abhijit Mukherjee has retired, effective March 31, 2018, the company said.
Mukherjee will be succeeded by Erez Israeli, former president and CEO of Enzymotec. Israeli will join Dr. Reddy's on April 2, 2018, as chief operating officer and global head of generics and PSAI, based out of Hyderabad.
Prior to Enzymotec, he completed 23 years with Teva Pharmaceuticals Ltd., where he held several positions of responsibility including vice president marketing and sales for North America, vice president Asia Operations, president Teva API, group executive vice president, head of global quality, and president and CEO growth markets.
Dr. Reddy's is committed to providing affordable and innovative medicines through its three businesses - pharmaceutical services and active ingredients, global generics, and proprietary products.
The company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, and differentiated formulations.
Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy's operates in markets across the globe, including the US, India, Russia and CIS countries, and Europe.